草酸铂联合卡培他滨治疗晚期胃癌的近期疗效分析  

The chemotherapy of oxaliplatin combined with capecitabine in advanced gastric cancers

作　　者：缪建华[1] 陈暑波[1] 张迦维[1] 杭猛[1] 

机构地区：[1]无锡市第二人民医院肿瘤科,江苏无锡214002

出　　处：《中国癌症杂志》2004年第5期439-440,共2页China Oncology

摘　　要：目的 :探讨草酸铂联合卡培他滨治疗晚期胃癌的近期疗效。方法 :对 32例晚期胃癌采用草酸铂联合卡培他滨方案治疗共 76周期。结果 :CR 6例 ,PR 16例 ,NC 8例和PD 2例 ,总有效率 (CR +PR)为 6 8.75 % (2 2 / 32 )。中位缓解期 8个月 ,中位生存期 12个月 ,1年生存率为 5 5 % ;临床受益者共 30例 (93.75 % )。不良反应可耐受 ,经积极对症治疗后均见好转 ,无相关死亡出现。无患者因为不良反应中止治疗。结论 :草酸铂加卡培他滨方案而组成的OX方案治疗晚期胃癌疗效较好 ,毒性反应能够耐受 ,可作为经济状况好的患者的一线方案在更多的病人中应用 。Purpose:To evaluate the short-term effect of combination chemotherapy of oxaliplatin plus capecitabine on advanced cancer.Methods:32 patients of advanced gastric cancer were treated with oxaliplatin plus capecitabine for 76 weeks.Results:There were 6 CR, 16 PR, 8 NC, 2 PD, in our group and the overall response rate was 68.75% (22/32). The median alleviative time was 8 months, the median survival time was 12 months and the one-year survival rate was 55%. 30(93.75%) patients benefited from this method. The side effects were all tolerable which were alleviated by active therapy. There was no death and nobody stopped chemotherapy because of side effects.Conclusions:Combination chemotherapy of oxaliplatin plus capecitabine to treat advanced gastric cancers was certainly effective and tolerable to toxicities. This chemotherapy will be used as the first-line in more patients and is worthy of further study.[

关 键 词：胃肿瘤 草酸铂 卡培他滨 化学治疗 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]